RELY:NASDAQRemitly Global, Inc. Analysis
Data as of 2026-04-28 - not real-time
$21.26
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Remitly (RELY) is trading at $21.26, just shy of its technical resistance around $21.39, while comfortably sitting above its 20‑day ($18.23), 50‑day ($16.91) and 200‑day ($15.93) moving averages – a classic bullish alignment. Momentum indicators reinforce the upside bias: the MACD line sits above its signal (1.39 vs 1.08) and the histogram is positive, yet the RSI has surged to 78, flagging an overbought condition that could temper short‑term gains. Volume is on an upward trend, supporting the price advance, and a recent “golden cross” has been highlighted in market chatter.
Fundamentally, RELY posted 25.7% year‑over‑year revenue growth with a healthy 60% gross margin, but profitability remains modest (operating margin 8.8%, profit margin 4.2%) and free cash flow is thin relative to operating cash flow. The trailing P/E of 68.6 dwarfs the industry average of 38, suggesting the stock is currently overvalued, yet the forward P/E of 13.9 and a consensus “strong buy” rating with a median target of $22 imply expectations of rapid earnings acceleration. Recent corporate developments – the appointment of Adam Messinger to the executive team and the upcoming Q1 earnings release on May 6 – provide fresh catalysts, while a director’s modest share sale at $15.99 underscores the price’s recent climb. Overall, the stock sits at a modest upside of ~4.5% per the DCF model, balancing bullish technicals against a high valuation baseline.
Fundamentally, RELY posted 25.7% year‑over‑year revenue growth with a healthy 60% gross margin, but profitability remains modest (operating margin 8.8%, profit margin 4.2%) and free cash flow is thin relative to operating cash flow. The trailing P/E of 68.6 dwarfs the industry average of 38, suggesting the stock is currently overvalued, yet the forward P/E of 13.9 and a consensus “strong buy” rating with a median target of $22 imply expectations of rapid earnings acceleration. Recent corporate developments – the appointment of Adam Messinger to the executive team and the upcoming Q1 earnings release on May 6 – provide fresh catalysts, while a director’s modest share sale at $15.99 underscores the price’s recent climb. Overall, the stock sits at a modest upside of ~4.5% per the DCF model, balancing bullish technicals against a high valuation baseline.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- RSI in overbought territory (78)
- Price near resistance at $21.39
- Upcoming Q1 earnings release
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Revenue growth of 25.7% YoY
- Forward P/E of 13.9 indicating earnings acceleration
- Analyst consensus strong‑buy with median target $22
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Large addressable market for cross‑border payments
- Strong cash position versus modest debt
- Strategic executive hire (Adam Messinger) enhancing growth outlook
Key Metrics & Analysis
Financial Health
Revenue Growth25.70%
Profit Margin4.16%
P/E Ratio68.6
ROE8.85%
ROA3.92%
Debt/Equity22.11
P/B Ratio5.2
Op. Cash Flow$325.1M
Free Cash Flow$6.1M
Industry P/E38.2
Technical Analysis
TrendBullish
RSI77.8
Support$15.00
Resistance$21.39
MA 20$18.23
MA 50$16.91
MA 200$15.93
MACDBullish
VolumeIncreasing
Fear & Greed Index89.25
Valuation
Fair Value$2.74
Target Price$22.22
Upside/Downside4.53%
GradeFair
TypeBlend
Risk Assessment
Beta1.18
Volatility39.35%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.